Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... marked the heavy market focus on the prospect of the White House imposing tariffs on imports from Mexico, Canada ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Citigroup wins appeal against military personnel over credit card rates Legalcategory· January 27, 2025 Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney ...

Novo Nordisk agreed to cap insulin prices to settle ... is returning to private legal practice after his wife's failed White House bid, joining corporate law firm Willkie Farr & Gallagher.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $150.0 for Novo Nordisk over the last 3 months.

Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight ...